Introduction
A large body of evidence links hemostatic variables to a higher risk of myocardial infarction and stroke. 1 Tissue factor (TF) is the major trigger of the coagulation cascade and leads to the activation of the coagulation cascade. Therefore, its inhibition by pharmacological or genetic interventions may be an attractive target for the treatment and prevention of cardiovascular diseases.
2 TF mediated activation of the coagulation cascade is inhibited by tissue factor pathway inhibitor (TFPI). Free tissue factor pathway inhibitor (TFPI-F) has been reported to be an important biomarker of myocardial damage. 3 In a study by Morange et al plasma TF levels were predictive of cardiovascular mortality in individuals with acute coronary syndromes (ACS), whereas TFPI-F levels were associated with the severity of myocardial damage on admission, but were not independently related to the outcome of these diseases. 4 Free TFPI directly inhibits factor Xa, 5 whereas surface-bound TFPI on endothelial cells inhibits TF and factor VIIa complex. 6, 7 Because TFPI is degraded by thrombolytics, a decreased anticoagulant activity may contribute to rethrombosis. 8 Activation of the fibrinolytic system by thrombolytic therapy in AMI decreases plasma TFPI. Reduced TFPI may contribute to thrombotic complications after fibrinolysis in AMI. 9 Significant relationships have been observed between markers of endothelial damage, thrombomodulin and TFPI.
10 TF indeed appears to be involved in the pathogenesis of neointima formation. Therefore, therapeutic strategies are under investigation to specifically interfere with the action of TF or, alternatively, promote the effects of TFPI. 2, [11] [12] [13] Clinical applications of such markers need to be tested in appropriate trials, in particular for evaluating the advantages of targeted versus systemic delivery of the inhibitors. This study was aimed to determine plasma levels of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in a cohort of Saudi patients with chronic stable angiographically defined coronary artery disease (CAD) and to determine its correlation with its severity. The study protocol was approved by the ethical Committee of College of Medicine Research Center. The individuals selected were informed about the objectives of the study and those patients who agreed to participate signed the consent form. A clinical record of each individual including personal data, demographic data, family history and results of the coronary angiography were filled in a predesigned proforma.
The inclusion criteria included adult patients of any sex with CAD, who had attacks of Angina or Myocardial infarction and underwent coronary angiography. Patients with nephrotic syndrome, acute or chronic renal failure, thyroid disorders, acute infections, stroke, diabetic ketoacidosis and non-ketotic hyperosmolar diabetes were excluded. In the control group, there were 39 healthy individuals matched for gender, age and BMI. All control subjects were free from clinical manifestations of coronary, peripheral or cerebral artery disease by history, physical examination and electrocardiographic findings.
A total of 60 patients completed the study. Overnight fasting blood samples were collected in sodium citrate tubes and plasma were separated within two to three hours after collection and stored at -80ºC until assayed. The control group had no past history of chest pain, family history or other evidence of CAD.
All patients underwent coronary angiography via the right femoral approach. Evidence of CAD presence was defined on the basis of at least 50% stenosis in a major coronary vessel. Gensini scoring system was used to determine the CAD severity. This scoring system considers the percentage and site of blockage and gives a score to each vessel under consideration. By assessing percentage of luminal narrowing and localization CAD, severity was graded.
14 The left main coronary artery, left anterior descending artery, circumflex and right coronary arteries were assessed. Multiple lesions in the same vessel were regarded as one-vessel disease. Vessel scoring was graded into single, double and triple vessel disease.
The plasma concentration of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor-1, plasminogen activator inhibitor 1 (PAI-1), and tissue plasminogen activator (t-PA) were measured by standard sandwich ELISA technique using commercial kits (Diagnostica STAGO, R.C.S. Nanterre, France).
The data were analyzed by computer software program Statistical Package for Social Sciences (SPSS version 10, Chicago). Differences between age, BMI and Blood pressure between the control and CAD subjects were analyzed by Student' s t-test. However, TFPI-T and TFPI-F, PAI-1, and t-PA because of their extreme skewness, were analyzed by non parametric Mann-Whitney U test. A p value of ≤0.05 was considered as statistically significant. Univariate and multiple regression analysis and Spearman' s correlation coefficients were determined between hemostatic markers and CAD severity.
Results
Clinical characteristics of all control and CAD patients are expressed in Table 1 . There were non-significant differences between age, BMI and Blood pressure between the controls and CAD subjects. Table 2 expresses comparison of hemostatic markers between the control and CAD patients. There were significantly higher levels of Fibrinogen (0.0253), PAI-1 (0.0466), TFPI-T (0.0001) and TFPI-F (0.0004) in CAD patients compared to control subjects. But the difference in plasma tPA (0.2811) levels was no significant. The mean Gensini score in all CAD patients was 76.99±6.75. CAD patients consisted of 17 subjects with single vessel disease, 20 subjects with double vessel disease, and 23 subjects with triple vessel disease. Table 3 shows Spearman' s correlations between Gensini Scoring, vessel scoring and hemostatic risk markers. It was observed that among different markers of hemostasis, only TFPI-T had a significant positive correlation with severity of disease determined by Gensini Scores (r=0.344; p=0.006) and vessel scores (r=0.338; p=0.015). Furthermore, the relationship with other markers was not significant. However, in multiple regression analysis, predictive power of TFPI-T for CAD severity became non significant (r=0.271; p=0.096). 
Discussion
In this study, we determined the relationship of markers of hemostasis with the presence and severity of angiographically defined CAD. Increased levels of TF have been detected in unstable angina, correlating with the presence of large areas rich in macrophages and smooth muscle cells (SMCs). 15 Therefore, the macrophage-rich atherosclerotic plaques (soft plaques), which have a high risk for rupture, 16 are at the same time prone to severe thrombosis because of the high expression of TF foam cells. 17 Our findings reinforce previous reports by Kaikita et al. suggesting that the presence of TFPI within the luminal surface of atherosclerotic lesions without disruption may play an active role in the prevention of thrombotic complications. 11 Morange et al. reported that high TFPI-F levels were not independently associated with an increased risk of cardiovascular death although it correlated significantly with its severity and concluded that only plasma TF levels were predictive of cardiovascular mortality in individuals with ACS. 6 The fact that TFPI co-localizes with TF on endothelial cells, smooth muscle cells and macrophages, and inhibits TF procoagulant activity serves as evidence that TFPI inhibits TF activity in the atherosclerotic vessel. 18 In a similarly designed study, TF and TFPI plasma levels and FVII coagulant activity were assessed in T2DM in relation to cardiothrombotic disease and their correlation to metabolic and clinical behavior of the patients. The authors reported significantly higher levels of TF and TFPI in diabetics without CAD and also with CAD. Moreover, there were significant correlations between high TF, TFPI plasma levels, FVIIa activity and cardiothrombotic complications in diabetic patients. 19 Reports also showed that serum Lp(a) and plasma total TFPI levels are elevated in patients with CAD. Caplice et al. 20, 21 showed that Lp(a) inhibits TFPI in vitro and concluded that Lp(a) binds TFPI with much higher affinity than plasminogen with which it shares structural similarity. Lp(a) also inactivates TFPI activity in the presence or absence of physiologic plasminogen concentrations. More than 90% of plasma TFPI is associated with lipoproteins, including Lipoprotein(a), LDL, and HDL. 7, 22 In our studied patients, we found higher levels of total TFPI, but not free TFPI. There are some controversial reports in the literature regarding the relationship of TFPI with CAD severity. Lima et al. found a significant correlation between TF and CAD severity but no correlation was observed with TFPI. However, Bilgen and colleagues reported a significant relationship between TFPI and CAD severity determined by vessel scoring. 23, 24 The associations of plasma levels of some hemostatic variables like fibrinogen, Von Willebrand factor, t-PA and Lp(a) with CHD risk are reported to be attenuated when inflammatory markers and conventional risk factors are included in multivariable analyses. Moreover, D-dimer and IL-6 each have the potential to increase the prediction of CHD, in addition to conventional risk factors. 25 The limitation of the current study is its cross sectional design and small sample size. Long term prospective trials are needed to determine the exact predictive value of these cardiovascular risk markers.
Conclusions
Plasma levels of total tissue factor pathway inhibitor are significantly related with the presence and severity of CAD. Elevated levels of TFPI-T may be considered as useful diagnostic and prognostic markers in patients with CAD.
